Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AGI-001; S-pindolol - AGI Therapeutics

Latest Information Update: 31 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AGI Therapeutics
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia

Most Recent Events

  • 19 Feb 2007 Discontinued - Phase-II for Irritable bowel syndrome in Ireland (PO)
  • 19 Feb 2007 Discontinued - Phase-II for Non-ulcer dyspepsia in United Kingdom (PO)
  • 03 Oct 2006 Interim results from a phase II clinical trial in patients with irritable bowel syndrome have been added to the adverse events and Digestive System Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top